The treatment against respiratory infection -gene therapy with SiRNA-

抗pcrv IgG可减少慢性铜绿假单胞菌呼吸道感染引起的过度炎症反应，如炎症细胞的募集和促炎细胞因子的产生。这些数据表明，抗pcrv IgG治疗可能对慢性铜绿假单胞菌呼吸道感染有用。Imamura Y, Yanagihara K，等。Eur.Respir.J。2007年出版)在没有抗炎作用的情况下，Telithromycin通过抑制生物膜的形成来减少活菌的数量。目前的数据还表明大环内酯类药物和酮内酯类药物对慢性呼吸道感染的影响存在差异。(Yanagihara K，等。化疗2007;53:10-13)西维司他延长了严重肺炎球菌肺炎模型的生存期。对生存率提高的一个可能的解释是，西司他通过抑制肺内NE的活性来防止组织损伤。由于这种损伤的减少，从血液中恢复的活菌数量在西司他组低于对照组。因此，西司他治疗可以改善死亡率。因此，NE抑制剂可能对治疗重症肺炎患者有用。(Yanagihara K，等。肺实验研究；33 (2): 71 - 80)

The anti-PcrV IgG reduced excessive inflammatory reactions, such as the recruitment of inflammatory cells and the production of pro-inflammatory cytokines, caused by chronic P.aeruginosa respiratory infection. These data suggest that treatment with anti-PcrV IgG may be useful in chronic P.aeruginosa respiratory infection. (Imamura Y, Yanagihara K, et al. Eur.Respir.J. 2007 in press)Telithromycin reduced the number of viable bacteria by inhibiting biofilm formation in the absence of an anti-inflammatory effect. The present data also indicated a difference between the effects of macrolides and ketolides against chronic respiratory infections. (Yanagihara K, et al. Chemotherapy 2007;53:10-13)Sivelestat prolonged survival in a severe pneumococcal pneumonia model. A possible explanation for the improved survival is that sivelestat prevents tissue damage by inhibiting NE activity in the lung. As a result of this reduced damage, the number of viable bacteria recovered from blood is lower in the sivelestat group than in the control group. Thus, improved mortality rates were seen with sivelestat treatment. NE inhibitors may therefore be useful in treating with patients with severe pneumonia. (Yanagihara K, et al. Experimental Lung Research, Mar;33(2):71-80)